1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
4.1. Product Pipeline
4.2. Patent Analysis
5. GLOBAL ANTI-VIRAL DRUG MARKET BY APPLICATION TYPE
5.1. Introduction
5.2. Herpes Antiviral Drugs
5.3. Hepatitis Antiviral Drugs
5.4. HIV Antiviral Drugs
5.5. Influenza Antiviral Drugs
5.6. Other Anti-viral Drugs
6. GLOBAL ANTI-VIRAL DRUG MARKET BY MECHANISM OF ACTION
6.1. Introduction
6.2. Nucleotide Polymerase Inhibitors
6.3. Reverse Transcriptase Inhibitors
6.4. Protease Inhibitors
6.5. Others
7. GLOBAL ANTI-VIRAL DRUG MARKET BY DISTRIBUTION CHANNEL
7.1. Introduction
7.2. Online
7.3. Offline
8. GLOBAL ANTI-VIRAL DRUG MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. By Application Type
8.2.2. By Mechanism of Action
8.2.3. By Distribution Channel
8.2.4. By Country
8.2.4.1. USA
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. South America
8.3.1. By Application Type
8.3.2. By Mechanism of Action
8.3.3. By Distribution Channel
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.2. Argentina
8.3.4.3. Others
8.4. Europe
8.4.1. By Application Type
8.4.2. By Mechanism of Action
8.4.3. By Distribution Channel
8.4.4. By Country
8.4.4.1. United Kingdom
8.4.4.2. Germany
8.4.4.3. France
8.4.4.4. Spain
8.4.4.5. Others
8.5. Middle East and Africa
8.5.1. By Application Type
8.5.2. By Mechanism of Action
8.5.3. By Distribution Channel
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.2. UAE
8.5.4.3. Others
8.6. Asia Pacific
8.6.1. By Application Type
8.6.2. By Mechanism of Action
8.6.3. By Distribution Channel
8.6.4. By Country
8.6.4.1. China
8.6.4.2. Japan
8.6.4.3. India
8.6.4.4. South Korea
8.6.4.5. Taiwan
8.6.4.6. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. F. Hoffmann-La Roche Ltd
10.2. Gilead Sciences, Inc.
10.3. Bristol-Myers Squibb Company
10.4. Pfizer Inc.
10.5. AstraZeneca plc.
10.6. AbbVie Inc.
10.7. Johnson & Johnson
10.8. Merck & Co., Inc.
10.9. Atea Pharmaceuticals
10.10. GlaxoSmithKline plc.
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations